An observational study in Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen and Positron Emission Tomography (PET), sponsored by Jiequn Yu. Completed at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by Jiequn Yu · Observational
The purpose of this study is to analyze heterogeneity of prostate cancer(PCa)based on the head-to-head imaging of prostate-specific membrane antigen (PSMA) and fluorodeoxyglucose (FDG) positron emission tomography computed tomography (PET/CT)
PET/CT examinations were performed on different days using Siemens Biograph MCT PET/CT equipment. All patients were examined on the same scanner. Patients were fasted for more than 6 h before [18F]FDG PET/CT examination, blood glucose was controlled below 11.1 mmol/L, [18F]FDG injection dose was 3.7 MBq/kg, and [18F]FDG PET/CT examination was performed after 60 min rest. [18F]PSMA-1007 injection dose was 3.7 MBq/kg, and PET/CT scan was performed 60 min after injection. To avoid interference of prostate lesion detection by active urine in the bladder, patients were asked to urinate or undergo forced diuresis before the start of the examination. The scan was performed from the top of the head to the base of the thighs. Low-dose CT was taken with automatic milliampere-second 120 kV voltage scans with a matrix of 512 × 512 and a thickness of 5 mm, and PET/CT image acquisition was taken from 5-6 beds for 2-3 min each. CT data was used for attenuation correction at the end of the acquisition, reconstructed by the two-iteration method (21 subsets in total), and the True X +TOF algorithm was applied to reconstruct the images. Two nuclear medicine physicians with extensive experience in PET/CT interpretation evaluated the images using the LIFEx software v 7.1.0. Both readers were blinded to both clinical and pathological data
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's enrollment of 45 is below the median of 200 across 1,181 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →This is the only study on the registry with Jiequn Yu as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Subjects treated at the First Affiliated Hospital of China Medical University
Exclusion Criteria:
patients with one type of PSMA+/FDG+ homogeneous segment
Diagnostic Test: PSMA PET/CT scan · Diagnostic Test: FDG-PET
patients with one type of PSMA-/FDG- homogeneous segment
Diagnostic Test: PSMA PET/CT scan · Diagnostic Test: FDG-PET
patients with one type of PSMA+/FDG- heterogeneous segment
Diagnostic Test: PSMA PET/CT scan · Diagnostic Test: FDG-PET
patients with one type of PSMA-/FDG+ heterogeneous segment
Diagnostic Test: PSMA PET/CT scan · Diagnostic Test: FDG-PET
Different developing agents
Different developing agents
The relationship between imaging phenotypes and gleason score (GS)
Time frame: From enrollment to the end of 1 month inspection
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.